Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tadalafil (Cialis) for men with erectile dysfunction.

I Eardley1, J Cartledge

  • 1Department of Urology, St James' University Hospital, Leeds, UK.

International Journal of Clinical Practice
|June 21, 2002
PubMed
Summary

Tadalafil, a novel phosphodiesterase type 5 inhibitor, shows efficacy in treating erectile dysfunction with a mild side-effect profile. Its long half-life and selectivity offer a promising treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A survey of how and why medical students and junior doctors choose a career in ENT surgery.

The Journal of laryngology and otology·2016
Same author

Significant benefit of a targeted HIV testing module on medical students' knowledge and confidence.

International journal of STD & AIDS·2015
Same author

Acceptability, feasibility and costs of universal offer of rapid point of care testing for HIV in an acute admissions unit: results of the RAPID project.

HIV medicine·2013
Same author

Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis.

International journal of clinical practice·2013
Same author

Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma.

British journal of cancer·2012
Same author

A case of oral ulceration and disseminated histoplasmosis in HIV infection.

International journal of STD & AIDS·2012

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Erectile dysfunction (ED) is a common condition affecting many men.
  • Phosphodiesterase type 5 (PDE5) inhibitors are a primary treatment for ED.
  • Sildenafil is a widely used PDE5 inhibitor, but alternative treatments are sought.

Purpose of the Study:

  • To evaluate the efficacy and safety of tadalafil, a new PDE5 inhibitor, for erectile dysfunction.
  • To compare the chemical structure and in vitro activity of tadalafil with sildenafil.
  • To assess the pharmacokinetic profile and duration of action of tadalafil.

Main Methods:

  • In vitro studies to determine PDE5 inhibition potency and selectivity.
  • Clinical studies to assess efficacy and safety in men with ED.
  • Pharmacokinetic analysis to determine half-life and duration of action.

Main Results:

  • Tadalafil demonstrated significant potency for PDE5 inhibition with minimal activity against other isoforms, including PDE6.
  • The drug has a half-life of 17.5 hours, with clinical efficacy observed up to 24 hours post-dosing.
  • Tadalafil was effective in treating ED, with a mild side-effect profile and no reported visual disturbances.

Conclusions:

  • Tadalafil is an effective and well-tolerated treatment for erectile dysfunction.
  • Its selective PDE5 inhibition and long duration of action offer advantages over existing therapies.
  • Tadalafil represents a promising new therapeutic option for men with ED.

Related Experiment Videos